(Total Views: 658)
Posted On: 04/10/2024 5:59:46 PM
Post# of 156015
Speaking of the FDA...Officials raise concerns with Immunotherapy overuse for early-stage cancer patients: AACR24___Endpoint News...San Diego.
Merck's Keytruda...speaking of the devil was the top selling drug in 2023...immunotherapy drug use has expanded as Big Pharmas have won approvaLs in earlier-stage cancer... by pairing them with surgery.
Apparently studies don't show how much of the load each part of the regimen carries. The concern is getting more drugs than necessary...and here's the punchline...getting "exposed to unnecessary side effects."
And of course...the old FDA dilemma... "we have more questions...than answers"
They are looking for the Goldilocks fix...good luck with that.
Merck's Keytruda...speaking of the devil was the top selling drug in 2023...immunotherapy drug use has expanded as Big Pharmas have won approvaLs in earlier-stage cancer... by pairing them with surgery.
Apparently studies don't show how much of the load each part of the regimen carries. The concern is getting more drugs than necessary...and here's the punchline...getting "exposed to unnecessary side effects."
And of course...the old FDA dilemma... "we have more questions...than answers"
They are looking for the Goldilocks fix...good luck with that.
(7)
(0)
